Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines

Nature Medicine

Volumn 3, Issue 4, 1997, Pages 395-401

  Freije, José M P ^a,c   Lawrence, Julia A ^a   Hollingshead, Melinda G ^b   De La Rosa, Abel ^a,d   Narayanan, Yen ^a   Grever, Michael ^a,e   Sausville, Edward A ^a   Paull, Kenneth ^a   Steeg, Patricia S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSIDAD DE OVIEDO   (Spain)

^d Digene Corporation   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; TUMOR MARKER;

ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; DRUG IDENTIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA; MOUSE; PRIORITY JOURNAL;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MELANOMA; MONOMERIC GTP-BINDING PROTEINS; NEOPLASM METASTASIS; NUCLEOSIDE-DIPHOSPHATE KINASE; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA;

EID: 0030897618     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0497-395     Document Type: Article

References (14)

1. Monks, A. et al. Feasibility of a high flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl.Cancer Inst. 83, 757-766 (1991).
2. Boyd, M. & Paull, K. Some practical considerations and applications of the National Cancer Institute In vitro Anticancer Drug Discovery Screen. Drug Dev. Res. 34, 91-109 (1995).
3. Paull, K. et al. Display and anlysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 81, 1088-1092 (1989).
4. Fitzsimmons, S. et al. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to Mitomycin C and EO9. J. Natl. Cancer Inst. 88, 259-269 (1996).
5. Paull, K., Lin, C., Malspeis, L. & Hamel, E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res. 52, 3892-3900 (1992).
6. Bai, R. et al. Halichondrin B and Homohalichondrin B, marine natural products binding in the vinca domain of tubulin. J. Biol. Chem. 266, 15882-15889 (1991).
7. Paull, K., Hamel, E. & Malspeis, L. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute, in Cancer Chemotherapeutic Agents, (ed. W.O. Foye) 9-45 (ACS, Washington, DC, 1995).
8. Weinstein, J.N. et al. An information-intensive approach to the molecular pharmacolocy of cancer. Science (in the press).
9. Alvarez, M. et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer institute Anticancer Drug Screen. J. Clin. Invest. 95, 2205-2214 (1995).
10. Steeg, P.S. et al. Evidence for a novel gene associated with low tumor metastatic potential J. Natl. Cancer Inst. 80, 200-204 (1988).
11. DeLaRosa, A., Williams, R.L. & Steeg, P.S. Nm23/nucleoside diphosphate kinases: Toward a structural and biochemical understanding of its biological functions. Bioessays 17, 53-62 (1995).
12. Leone, A. et al. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 65, 25-35 (1991).
13. Leone, A., Flatow, U., VanHoutte, K. & Steeg, P.S. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: Effects on tumor metastatic potential, colonization, and enzymatic activity. Oncogene 8, 2325-2333 (1993).
14. Parhar, R.S. et al. Effects of cytokine mediated modulation of Nm23 expression on the invasion and metastatic behavior of B16F10 melanoma cells. Intl. J. Cancer 60, 204-210 (1995).